Ankle & Foot Injuries: What the Evidence Shows

Scope of This Review

The ankle and foot are one region containing several unrelated problems. Achilles tendinopathy, Achilles rupture, plantar fasciitis, osteochondral lesions of the talus and lateral ankle instability share an anatomical neighbourhood and nothing else — different tissues, different mechanisms, different prognoses and, importantly here, very different evidence.

This page keeps them separate. Evidence generated for one condition is never used to support another, and where a condition has no clinical evidence for a treatment, the page says so rather than borrowing from a neighbour.

It also keeps platelet-rich plasma (PRP) and cell therapy distinct. In this region they are not interchangeable, and the stronger evidence does not belong to the one usually marketed harder.

The Conditions, Separately

Lateral ankle sprain and chronic instability

Ankle sprain is among the most common musculoskeletal injuries. In a US national surveillance database, 3,140,132 ankle sprains presented to emergency departments over the five years 2002–2006 — an incidence of 2.15 per 1,000 person-years, peaking at 7.2 per 1,000 in those aged 15–19⁷. Those are emergency presentations; many sprains never reach a hospital.

The injury usually damages the lateral ligament complex, particularly the anterior talofibular ligament, when the foot is forcefully inverted. Grade I injuries generally settle with conservative care. The clinically important problem is recurrence: acute ankle sprains have a high recurrence rate, and recurrence is associated with the development of chronic ankle instability, which in turn is linked to post-traumatic osteoarthritis⁸.

Achilles tendinopathy

The Achilles is subject to large repetitive loads during normal locomotion⁹. Midportion tendinopathy involves collagen disorganisation, neovascularisation and increased ground substance — a degenerative process rather than a straightforwardly inflammatory one.

Acute Achilles rupture

Incidence of acute Achilles rupture has been rising, while the proportion treated surgically has fallen — a nationwide registry study of 33,160 patients documented both trends between 1994 and 2013¹⁰.

Re-rupture is the feared complication. In a consecutive series, 48 of 783 patients with a primary rupture went on to re-rupture (6.1%), at a median of 98.5 days. Male sex and younger age were risk factors — and so was traditional immobilising rehabilitation¹¹. That last one is modifiable, and it matters more than it sounds; see the comparator section below.

Plantar fasciitis

Plantar fasciitis is a common cause of heel pain, involving degeneration and micro-tearing of the plantar fascia at its calcaneal insertion¹². Chronic cases typically show degenerative rather than inflammatory histology, which is part of why anti-inflammatory approaches often disappoint.

Osteochondral lesions of the talus

These involve damage to both articular cartilage and the underlying subchondral bone, usually after ankle trauma. Cartilage has minimal intrinsic healing capacity, and the talar dome's blood supply is limited — which is why this lesion is generally managed surgically rather than expectantly.

Peroneal and posterior tibial tendon disorders

The peroneal tendons laterally and the posterior tibial tendon medially are susceptible to tenosynovitis, longitudinal tearing and rupture. Posterior tibial tendon dysfunction is a leading cause of acquired adult flatfoot, progressing from tenosynovitis through flexible to rigid deformity. There is no cell-therapy or PRP trial evidence specific to these tendons, and none of the evidence below applies to them.

Why These Tissues Heal Badly

Tendons and ligaments are hypovascular, supplied mainly through the paratenon or through their bony attachments. Limited vascularity restricts delivery of reparative cells and growth factors. The Achilles midportion sits in a relative watershed zone, which is part of why degenerative change concentrates there.

When these tissues do heal, they produce scar rather than replacement tissue. Normal tendon is predominantly type I collagen in highly organised parallel fibres. Healing tendon contains a mixture of types I and III with disorganised architecture and increased ground substance — mechanically inferior, and more prone to re-injury.

In chronic conditions the normal inflammatory → proliferative → remodelling cascade appears to arrest in a dysfunctional state, producing persistent symptoms without effective restoration.

This biology is the rationale for regenerative approaches. A rationale is a reason to run trials. The trials have been run, and their results are below.

What Regenerative Treatments Are Meant to Do

Mesenchymal stromal cells are understood to act mainly through paracrine signalling rather than by incorporating into repair tissue: secreting factors that activate resident tenocytes, encourage more organised collagen deposition, promote local vascularisation, and modulate inflammation¹³.

Two corrections to descriptions commonly seen. MSCs are immune evasive, not immune privileged — allogeneic cells can be given without donor matching, but they are cleared by the recipient¹⁴. And their capacity to travel to and remain at an injury site is limited, so "systemic infusion will find the injury" is not a supportable claim.

Achilles Tendinopathy: The Evidence Is Negative

This is the condition most often marketed for injection therapy in this region, and it has been tested properly.

A participant-blinded, multicentre randomised clinical trial enrolled 240 people across 24 sites with midportion Achilles tendon pain of more than three months, confirmed on ultrasound or MRI. Participants received either a single intratendinous PRP injection (n = 121) or a sham injection — a subcutaneous dry needle not entering the tendon (n = 119). The primary outcome was the VISA-A score at six months, a composite of pain, function and activity, for which the minimal clinically important difference is 12 points. Ninety-two per cent completed the trial¹.

Cell therapy has been tested too. A systematic review of 22 clinical studies and 658 patients across five tendon sites reports that for Achilles tendinopathy, the only randomised controlled trial found that both the cell-therapy and control groups showed significant pain reduction and functional improvement, with no statistical difference between them at six months — though the cell-therapy group improved faster at earlier timepoints².

That is the state of the evidence: both groups get better, and the treatment does not explain why.

For acute rupture

PRP has also been tested in acute Achilles rupture. A randomised, placebo-controlled, participant- and assessor-masked superiority trial enrolled 230 adults across 19 UK hospitals with acute rupture managed non-surgically, randomising to PRP (n = 114) or dry-needle placebo (n = 116), with all participants receiving standard rehabilitation. The primary outcome was muscle-tendon function at 24 weeks, measured objectively as limb symmetry index in work done during a heel-rise endurance test³.

Both trials are large, blinded and placebo- or sham-controlled. They are the appropriate basis for a decision about the Achilles, and they outrank any mechanism argument.

Plantar Fasciitis: Where the Evidence Is Actually Positive

The region's best-evidenced injectable is PRP, and the condition is heel pain.

A systematic review and meta-analysis of Level 1 and 2 studies — 15 studies — compared intralesional PRP with corticosteroid injection⁴:

The shape of that table is the useful part: corticosteroid does at least as well early, and PRP overtakes it from three to six months and holds the advantage at a year. If the problem is short-term relief, that is an argument for steroid; if it is durability, it is an argument for PRP.

The authors' caveat belongs with the result: 9 of the 15 studies were at high risk of bias, with one study rated high quality, nine moderate, two low and three very low. The direction is consistent; the certainty is moderate at best.

Osteochondral Lesions of the Talus: Cell Therapy as a Surgical Adjunct

This is the strongest cell-therapy indication in the foot and ankle, and its framing matters.

A systematic review retrieved data from 477 procedures in which surgical treatment of talar chondral defects was augmented with cell therapy. At a mean follow-up of 34.8 ± 9.7 months⁵:

• VAS pain improved by 4.4 points out of 10 (P = 0.002)
• AOFAS function improved by 31.1 points out of 100 (P = 0.0001)
• Tegner activity score did not improve (P = 0.4)
• No graft delamination or hypertrophy was observed; few articles reported complication data

Three things follow. The pain and function gains are substantial and statistically robust. The activity-level score — arguably what an athlete cares about most — did not move. And these were surgical procedures with cell augmentation, not injections offered as an alternative to surgery. The review's authors call for randomised controlled trials with larger populations and longer follow-up.

The Comparator: Surgery Versus Conservative Care for Achilles Rupture

This deserves its own section because the conventional summary is out of date.

A meta-analysis of 10 randomised trials compared surgical with non-surgical treatment of acute Achilles rupture⁶:

• Where functional rehabilitation with early range of motion was used, re-rupture rates were equal — risk difference 1.7%, P = 0.45
• Where early range of motion was not used, surgery reduced re-rupture by an absolute 8.8% (P = 0.001)
• Surgery carried an absolute 15.8% increase in other complications (P = 0.016, favouring non-operative management)

The advantage historically attributed to surgery largely reflects the rehabilitation protocol it was compared against. With modern functional rehabilitation, the re-rupture difference disappears and the complication difference favours non-operative care. The re-rupture epidemiology points the same way: traditional immobilising rehabilitation is itself a risk factor¹¹.

For a patient, this reframes the question. It is less "surgery or not" than "what rehabilitation protocol", and that is a conversation to have with a foot and ankle surgeon.

Putting It Together

The honest summary: the strongest regenerative claim in the foot and ankle concerns PRP for heel pain, and the strongest cell-therapy claim concerns surgical augmentation of talar cartilage lesions. Neither is about injecting stem cells into an Achilles tendon.

What Sterling-Certified Partner Clinics Offer

For transparency, separately from the evidence above: partner clinics provide platelet-rich plasma preparation and image-guided injection, allogeneic umbilical cord-derived MSC preparations under Thai FDA oversight, and diagnostic imaging review. Session structure, cell counts, preparation method, pricing and adjunct services are commercial and clinical arrangements determined at the clinic. They are not findings from the literature and are not presented here as evidence of effect.

Adjunct offerings — including NAD+ infusion, NK/NKT cell preparations, plasmapheresis and cord blood plasma — have no published clinical evidence supporting their use for ankle or foot injury, and form no part of the evidence base described here.

Note that almost all published cell-therapy evidence in tendon disorders used autologous cells²; allogeneic umbilical cord preparations are largely untested in this region.

Any treatment plan is a matter for a qualified clinician who has examined you and reviewed your imaging.

Frequently Asked Questions

Does stem cell therapy work for Achilles tendinopathy?

The one randomised controlled trial found no statistical difference from control at six months — both groups improved². PRP has also been tested against sham injection in a 240-patient multicentre trial¹. This is a condition where the evidence has been sought and has not been favourable.

How does this compare with PRP?

For the foot and ankle specifically, PRP has the larger clinical evidence base — a 15-study meta-analysis in plantar fasciitis⁴ and two large randomised trials in the Achilles¹ ³. Cell therapy's best evidence here is a systematic review of surgically augmented talar procedures⁵. The common claim that cell therapy is simply "more potent" than PRP is not what the evidence in this region shows.

What about my heel pain?

This is the most favourable answer on the page. PRP outperformed corticosteroid injection on function at 6 and 12 months and on pain at 3, 6 and 12 months across 15 studies — with the caveat that most of those studies carried a high risk of bias⁴.

I have a cartilage lesion in my ankle. Does cell therapy help?

The evidence is the most encouraging for cell therapy in this region: pain improved by 4.4 VAS points and function by 31.1 AOFAS points across 477 procedures⁵. Two qualifications: activity level did not improve, and this was cell therapy added to surgery, not used in place of it.

Should I have surgery for an Achilles rupture?

That is a decision for a foot and ankle surgeon, and the evidence has shifted. With functional rehabilitation and early range of motion, re-rupture rates are equal between surgical and non-surgical management, and surgery carries a 15.8% absolute increase in complications⁶. The rehabilitation protocol matters more than the older summaries suggest¹¹.

Can I have this if I have already had surgery?

There is no trial evidence in patients with failed surgical outcomes for any of these conditions. Anyone offering treatment on that basis is extrapolating.

Is there a rejection risk with umbilical cord cells?

Allogeneic MSCs can be given without donor matching, but they are immune evasive rather than immune privileged — they are cleared by the recipient rather than tolerated indefinitely¹⁴. Separately, note that this region's published evidence almost entirely used autologous cells².